Skip to content
Search

Latest Stories

Lenders to vote on Hinduja Group’s resolution plan for Reliance Capital

Indusind International Holdings has offered around £960m to buy the company which was once controlled by Anil Ambani

Lenders to vote on Hinduja Group’s resolution plan for Reliance Capital

Reliance Capital’s lenders have decided to vote on a resolution plan submitted by a Hinduja Group company.

Indusind International Holdings Ltd (IIHL) offered around Rs 100 billion (£960 million) to buy the company which went into administration in November 2021 after defaulting on a debt repayment of Rs 240 bn (£2.31 bn).


The Hinduja entity earlier week submitted its resolution plan for the financial services company which is lower than its liquidation value estimated between Rs 125 bn (£1.20 bn) and Rs 130 bn (£1.25 bn), media reports said.

Other bidders, including Torrent Investments, Oaktree Capital and Piramal Capital did not submit detailed plans before the deadline set by the lenders, the Economic Times reported.

Without naming IIHL, Reliance Capital administrator Nageswara Rao Y said the committee of creditors “deliberated the resolution plan received from one of the prospective resolution applicants” at their meeting on Wednesday (7).

The resolution plan would be put for e-voting under the insolvency and bankruptcy code, he said in a filing to the Bombay Stock Exchange.

At least two-thirds of the creditors need to favour the plan to take it forward to the National Company Law Tribunal for approval.

If it passes the hurdles, the resolution plan further requires approval from the Reserve Bank of India - the banking regulator.

The sale of the company is subject to the Supreme Court's decision on a suit filed by Torrent Investments over the extension of the deadline for the auction of Reliance Capital, which was once controlled by Anil Ambani.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less